In just three weeks, Biogen (NASDAQ: BIIB) gave up most of the gains its stock had built over the past 12 months. The general stock market pullback was one factor behind the decline, of course. However, Biogen also had its own issues that were even more significant.Should investors consider buying Biogen stock on the dip?